Hepatitis C virus infection in dialysis and clinical nephrology
Hepatitis C Virus (HCV), a single-strand RNA virus, has recently been cloned and sequenced (1) (2) . It causes nearly all cases of non-A non-B post-transfusion hepatitis (NANBH) (3) , and is responsible for most of the community-acquired NANBH (4) . Considerable progress has been made in characterizing HCV and understanding the prevalence, transmission, and natural history of HCV infection.
Tests for HCV infection
At present HCV infection is routinely diagnosed by indirect methods such as enzyme immunoassays, which detect serum antibodies against HCV antigens. First-generation screening and confirmatory assays that use as antigen a recombinant protein (c100-3) from the NS4 region of the viral genome were developed in 1990. The identification of other immunogenic regions of HCV encoded proteins led to the development of second-generation screening and confirmatory immunoassays. These included recombinant antigens from the NS3 region (c200) and from the capsid region (c22-3), in addition to c100-3. Thirdgeneration screening and confirmatory tests were most recently licensed in order to improve the sensitivity and specificity of the assays. ELISA 3 rd generation uses recombinant antigens from four different regions of the viral polyprotein (capsid: C22-3, NS3/ NS4: c200, NS5), while in RIBA-3 two recombinant proteins are replaced by synthetic peptides: c-22(p) and c100(p). Compared with 2 nd generation assays, the original c100-3 protein is only present as a subunit of the c200 protein. The NS5 protein, derived from the nonstructural region of the genome encoding the viral polymerase, is also added.
The relatively low titre of HCV in most patients does not allow efficient detection of HCV antigens (5) . The only method to detect viremia is specific detection of HCV RNA. This can be achieved by direct detection of HCV RNA by slot blot hybridization to radiolabelled riboprobes (6), on inside hepatocytes by in situ hybridization (7). However, the sensitivity of these methods is low. Currently, HCV RNA is commonly assayed by a combined reverse transcription and polymerase chain reaction (RT-PCR) aimed at the well preserved 5'UTR, which allows the use of universal primers for all HCV genotypes. This method is very sensitive and allows detection of minute quantities of HCV RNA in plasma pools (8). Furthermore, during the early phase of primary HCV infection, HCV RNA is the only diagnostic marker of infection (9-10). HCV RNA detection correlates well with viremia and can predict infectivity, but lack of PCR positivity does not completely rule out infectivity (11-13).
A variety of RT-PCR assays for HCV RNA detection have been described and allow HCV RNA detection in plasma and liver samples (14) . To enhance sensitivity, the size of the PCR product can be reduced (15) , or nested PCR can be performed (16) (17) (18) (19) (20) . Using sense eDNA primers, RT-PCR allows specific detection of antigenomic HCV RNA, indicative of viral replication (21) . Despite the availability of a wide range of RNA isolations and PCR primer combinations (22) (23) (24) , the reliability of RT PCR for diagnosis of HCV viremia remains a problem in several laboratories, as suggested by a recent quality control study (25) . Furthermore, the handling and storage of blood samples suitable for HCV RNA detection must be standardised to prevent degradation of HCV RNA (26-27).
HCV RNA quantitation will also become more important, because it can have significant clinical implications (28). High concentrations of HCV RNA seem to have a negative predictive value of the efficacy of interferon treatment in chronic HCV infections (29-30) and the relation between viral titre and infectivity of body secretions. Quantitative analysis of HCV RNA can at present be achieved by two methods. Competitive PCR employs a modified RNA transcript or eDNA, which is processed along with the sample of interest in serial dilutions (31-32). An alternative method is not based on RT PCR but uses specific capture of HCV RNA, followed by detection with branched DNA molecules (bONA), providing signal amplifications (33). At present HCV RNA quantitation is possible, but it needs considerable technical improvements to achieve widespread application. Phylogenetic analysis of nucleotide sequences derived from part of the gene encoding a non-structural protein (NS5) has provided evidence for six major genotypes of HCV. Many of these HCV types comprised a number of more closely related subtypes, leading to a current total of 11 genetically distinct viral populations (34). At present, it could be important to perform HCV genotyping in anti-HCV positive patients with detectable HCV RNA in serum. This is because different HCV genotypes may have different clinical relevance, such as response to interferon treatment (35-39) and risk to develop cirrhosis or 236 hepatocellular carcinoma. Moreover, different HCV genotypes may evoke different serological responses (40) . Genotype-specific antibodies have been found to react with the core protein (41), the NS4 protein (42) (43) (44) and the E1 envelope protein (45) . Specificity however is still low, preventing routine applications, so that genotyping by RNA analysis remains the only available technique for HCV genotyping. Currently, HCV genotyping can be achieved by type-specific polymerase chain reaction primers (35, 46), direct sequencing (47) (48) , restriction fragment length polymorphism (RFLP) (49) , southern blot hybridisation with type-specific probes (50-51), or reverse hybrid isation to (sub)type-specific probes (52) . Although different HCV nomenclatures are in use (34, 53); the classification system proposed by Simmonds et al (34), based on sequence alignments of a large number of HCV sequences derived from several parts of the genome, has been accepted by several HCV research Information about use of third-generation screening and confirmatory assays in renal patients is lacking (71) . The prevalence of anti-HCV positivity In kidney transplant recipients is comparable with the anti-HCV prevalence in hemodialysis patients, as suggested by some authors (72) (73) (74) (75) (76) (77) (78) (79) (80) . In these reports, the number of blood transfusions before transplantation was identified as an important risk factor. The prevalence of anti-HCV positivity in patients on CAPD (continuous ambulatory peritoneal dialysis) is significantly lower compared to HD patients, indicating that CAPD patients are at lower risk of acquiring HCV infection (81) (82) (83) (84) (85) (86) (87) . Several factors could contribute to this difference: CAPD is primarily a home procedure, and this may limit the risk of acquiring HCV infection by nosocomial spread. Nosocomial spread is an important risk factor for HD patients (88) (89) (90) (91) (92) . Data from the Lombardy Regional Dialysis and Transplant Registry (93) indicates the seroconversion for anti-HCV after a 24-month follow-up period occurred in 69 of 2,404 patients (2.8%). The frequency of patients who did not show seroconversion for anti-HCV after this follow-up period was lower in HD compared to peritoneal dialysis treatment (hemodialysis 95.6%, peritoneal dialysis 98.1%). The prevalence of anti-HCV positivity among HD and CAPD patients attending our dialysis unit was 24% (68) and 12% (87), respectively, using second-generation screening and confirmatory assays.
HCV in CRF patients not requiring dialysis treatment
There is by contrast very little information (94-96) about HCV infection in chronic renal failure patients not yet requiring dialysis. We previously studied (96) a large cohort of CRF patients (221 patients) not requiring dialysis and we found a prevalence of anti-HCV antibodies of 20%. This observation was confirmed by the data of the Lombardy Regional Dialysis and Transplant Registry (93) . It reported a prevalence of anti-HCV positivity in patients at the beginning of HD treatment (duration of HD treatment, 0-12 months) of 13% (94/715 patients). This finding is very high compared (97) to the prevalence of anti-HCV among blood donors of Northern Italy (1.28%). Information regarding seroprevalence in the general population is very scarce; there are few reports, based on small patient groups. A study carried out in 812 subjects attending a clinical analysis laboratory in Northern Italy for tests not for liver disease showed a prevalence of 2.9% for anti-HCV (98) . Therefore, CRF patients must be considered a high-risk group for HCV infection. In our analysis (96), anti-HCV positivity was related to blood requirements, past or current elevations of aminotransferase levels, and to a less degree, the duration of CRF. Such patients, indeed, often receive many transfusions for the anemia of chronic renal failure. On the other hand, many of them are also frequently hospitalized and could thus acquire HCV by nosocomial spread. Clearly further studies are needed to determine which mute of transmission is most important. In these patients some of the diagnostic and therapeutic procedures such as biopsies, artero-venous fistulae, venoclysis, subclavian or femoral or jugular catheterism) could well account for their anti-HCV positivity. Furthermore, several of these patients also have compromised immunity due to immunosoppressive treatment. Within the next few years it should be possible to evaluate such relevant epidemiological data, and the prevalence of anti-HCV should be further reduced after screening of blood products for anti-HCV and more extensive use of recombinant erythropoietin in CRF patients on conservative therapy. The strong association between anti-HCV positivity and raised aminotransferase concentrations we observed was most probably a consequence of HCV infection rather than a cause, also among HD patients. Some authors reported the presence of liver cirrhosis in anti-HCV positive patients on HD treatment, but they observed a very limited number of cases (99) (100) . HD patients are less likely to develop this complication due to their reduced life expectancy. CRF patients with HCV-seropositivity, however, could develop this complication due to prolonged life expectancy compared to HD patients. There are no data regarding biopsy-proven HCV chronic hepatitis in these patients, and information regarding virological features of HCV infection in predialysis CFR subjects is needed. We observed (101), indeed, a poor association between anti-HCV and HCV RNA in HD population; this finding was confirmed by other authors in HD populations (102) (103) (104) (105) (106) . Other investigators are in disagreement With these observations (107) . Moreover, we showed (101) that serum AL T levels were a poor predictor of liver disease in HD patients. By contrast, we found (108) a good association between anti-HCV and HCV RNA in kidney transplant recipients attending our unit, and serum AL T levels were a good predictor of liver disease in this high-risk population. So far there are no studies in pre-dialysis CRF patients that can clarify these problems. It will necessary, then to study this patient group, because many of these patients, being affected by progressive chronic renal failure, 238 may need dialysis treatment and could become a source of HCV spread in dialysis units. The high prevalence of anti-HCV in CRF patients, who often require hospital admission, poses a potential risk for HCV infection to the nurses who care for such renal patients at large, and not only for the dialysis patients themselves.
HCV and glomerulonephritis
Various extrahepatic syndromes have recently been reported with chronic HCV infection. These include Sjogren-like sicca syndrome (109) . porphyria cutanea tarda (110) , autoimmune thyroiditis (111), polyarteritis nodosa (112) (113) , and rheumatoid arthritis (114) . HCV is now known to be the major cause of mixed cryoglobulinemias (115) (116) (117) and of cryoglobulinemic glomerulonephritis. This usually assumes the form of a membranoproliferative glomerulonephritis. Its pathogenetic mechanism may be the deposition of immune complexes containing HCV, IgG anti-HCV antibody, and IgM rheumatoid factor in the glomeruli.
A preliminary report from the Lombardy Regional Dialysis and Transplant Registry (118) described a high frequency of anti-HCV among HD patients with chronic glomerulonephritis (36%) compared to HD patients with other underlying nephropathies: diabetic nephropathy 26%, vascular diseases 21%, hereditary diseaes 29%, unknown cause 29%, systemic disorders 36%. Such observation is apparently in accordance with several reports describing possible associations between HCV infection and glomerulonephritis. At present, indeed, several authors (119) (120) (121) (122) (123) (124) (125) observed the association between HCV infection and cryoglobulinemic glomerulonephritis. However data regarding HCV infection and other types of glomerulonephritis are lacking. There are some reports describing few HCV positive patients with noncryoglobulinemic membranoproliferative glomerulonephritis, diffuse proliferative glomerulonephritis and membranous nephropathy (126) (127) (128) (129) . In such patients HCV could play an etiological role in the development of renal disease. On the contrary, there are only preliminary reports describing the prevalence of anti-HCV antibodies in large cohorts of patients with primary glomerulonephritis, and these authors observed coflicting results. We prospectively studied (130) the prevalence of anti-HCV antibodies in a large group (132 cases) of patients with biopsy-proven idiopathic and secondary glomerular disease: the prevalence of anti-HCV antibodies was 12% (13/105) in patients with primitive glomerulonephritis, and 37% (10/27) in patients with secondary glomerular disease. All patients with cryoglobulinemic membranoproliferative glomerular disease showed anti-HCV antibody. Further, we observed a high prevalence of anti-HCV antibody in patients with membranous nephropathy and, to a less degree, in patients with IgA nephropathy. On the contrary, other authors (131) observed no anti-HCV antibodies in their patients with primary glomerulonephritis. Other investigators, instead, (132) found a very low prevalence of anti-HCV antibodies in patients with IgA nephropathy. Moreover, no HCV antibodies were found in a cohort of patients with rapidly progressive glomerulonephritis (133). A wide variation in the prevalence of anti-HCV antibodies in the general population at a regional level could partially account for these conflicting data. Alternatively, a biased collection of patients could be the cause of these different results. Cryoglobulins and liver histology in patients with HCV-associated glomerulonephritis have not been completely investigated (134) . Further prospective studies are required to clarify the association between HCV infection and idiopathic glomerulonephritis. Furthermore, the optimal treatment strategy for patients with HCV-associated glomerular disease has yet to be evaluated. The efficacy of antiviral therapies, such as alpha-interferon and alternative antiviral drugs, is under investigation (135) (136) (137) (138) . 
